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What’s already known about this topic 
Organ transplant recipients have a highly increased risk of cutaneous squamous cell 
carcinomas. Sensation of pain in cutaneous tumours is a powerful patient-reported warning 
signal for invasive cutaneous squamous cell carcinomas in organ transplant recipients. The 
question is whether painful lesions and the development of squamous cell carcinomas can 
predict the prognosis quoad vitam. 
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What does this study add 
Organ transplant recipients have an increased overall mortality risk if they develop painful 
skin lesions or are diagnosed with cutaneous squamous cell carcinomas. This finding 
highlights the need for close and long-term follow-up of organ transplant recipients who 
present with cutaneous squamous cell carcinomas or painful skin lesions in view of the 
higher overall mortality risk observed in these patients. 
 
Abbreviations: 
SCC: squamous cell carcinoma 
BCC: basal cell carcinoma 
KA: keratoacanthoma 
OTR: organ transplant recipients 
CI: confidence interval 
SCOPE: Skin Care in Organ transplant Patients Europe 
ITSCC: International Transplant Skin Cancer Collaborative 
 
 
Abstract 
Background: Organ transplant recipients have a highly increased risk of cutaneous squamous 
cell carcinomas. Sensation of pain in cutaneous tumours is a powerful patient-reported 
warning signal for invasive cutaneous squamous cell carcinomas in organ transplant 
recipients. 
Objectives: The impact of painful compared to painless skin lesions and cutaneous squamous 
cell carcinoma (SCC) compared to other skin lesions on the overall mortality risk in organ 
transplant recipients (OTR) was investigated.  
Methods: We followed 410 OTR from 10 different centres across Europe and North America 
during the period between 2008 and 2015. These patients had been enrolled in an earlier 
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study to define clinically meaningful patient-reported warning signals predicting the presence 
of SCC and had been included if they had a lesion requiring histological diagnosis. 
Cumulative incidences of overall mortality were calculated using Kaplan-Meier survival 
analysis and risk factors were analysed with Cox proportional hazard analysis.  
Results: There was an increased overall mortality risk in OTR who reported painful compared 
to painless skin lesions with a hazard ratio adjusted for age, sex, and other relevant factors of 
1.6 (95% CI 0.97-2.7). There was also an increased overall mortality risk in OTR diagnosed 
with SCC compared to other skin lesions with an adjusted hazard ratio of 1.7 (95% CI 1.0-
2.8). Mortality due to internal malignancies and systemic infections appeared to prevail in 
OTR with SCC.  
Conclusions: We suggest that OTR have an increased overall mortality risk if they develop 
painful skin lesions or are diagnosed with cutaneous SCC.  
 
Introduction 
It has been well documented that organ transplant recipients (OTR) have a highly increased 
risk of cutaneous squamous cell carcinomas (SCC) compared to the general 
immunocompetent population, with reported increased risks of up to 50 to 100-fold.1-3 In a 
previous study conducted by SCOPE (Skin Care in Organ transplant Patients Europe) and 
ITSCC (International Transplant Skin Cancer Collaborative) we reported that sensation of 
pain in cutaneous tumours is a powerful patient-reported warning signal for invasive 
cutaneous SCC in OTR.4 Pain has, therefore, been identified as a key feature of SCC in 
OTR.4;5 This important symptom helps to empower patients to seek treatment earlier.  
Other skin conditions such as basal cell carcinoma (BCC) can present with pain as 
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well,5 but we could not confirm this in the SCOPE-ITSCC PAIN study.4 Pain in general has 
also been reported to be associated with an increased risk of mortality, although the exact 
relationship is unclear and there is paucity of published data to date.6-8 Earlier studies showed 
that OTR with cutaneous SCC have an increased risk of mortality from both malignancy and 
other causes.9-11 Increased overall mortality after SCC may not be explained by the 
occurrence of intervening cancers alone, but perhaps reflects a more general predisposition to 
life-threatening illnesses.12 
In the current study we intended to study the fate of OTR who presented with a 
painful compared to a painless skin lesion and with a cutaneous SCC compared to other skin 
lesions with regard to: 1) the development of subsequent SCC and/or BCC and 2) their risk of 
overall mortality. Improving our understanding of the fate of painful skin lesions and the 
burden of SCC in OTR is important, since these lesions can be found in a significant 
proportion of OTR, and are increasing with duration after transplantation.  
 
Patients and Methods 
The original SCOPE-ITSCC PAIN study was performed between July 2008 and February 
2011 in 10 centres dedicated to surveillance of OTR with skin problems in Europe and the 
United States.4 This investigator-sponsored study was designed by the principal investigators 
and emerged from a joint initiative between SCOPE, (http://www.scopenetwork.org/) and 
ITSCC (http://www. itscc.org/). Each site’s independent ethics committee or institutional 
review board approved the protocol and participants gave informed consent in accordance 
with the Declaration of Helsinki.  
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OTR could be included if they had a lesion requiring a histological diagnosis. Inclusion did not 
depend on the past clinical history. The study was designed to define clinically meaningful patient-
reported warning signals predicting the presence of SCC. Painful lesions compared to painless lesions 
appeared to be the most powerful patient-reported warning signal for invasive SCC in OTR. The 
questions in the original study covered different aspects of pain: spontaneous pain (without 
touch or palpation); tenderness by touching or palpation (no spontaneous pain), intensity of 
pain on a visual-analog scale from 0 to 10 where 0 denotes no pain and 10 strongest pain, 
pain disturbing sleep as well as itching and bleeding of the lesion. For the current study 
spontaneous pain and tenderness by touching or palpation were combined as painful lesions 
and compared with painless lesions. In the original study, multiple biopsies could be taken 
during the first visit and additional biopsies could be taken during follow-up visits. This 
resulted in the inclusion of 410 patients with altogether 812 skin biopsies. 
 
Data collection 
In the current study, further clinical data in the period between 2007 and 2015 for patients 
enrolled in the initial SCOPE-ITSCC PAIN study cohort were collected. These additional 
data consisted of the dates of subsequent biopsies, the body location and the histological 
diagnosis (SCC/KA, BCC, Bowen’s disease, or other skin tumours). The total numbers of 
tumours with different histologic subtypes for each patient were also captured. The 
occurrence of locally aggressive SCC, metastasis and death were recorded. Locally 
aggressive SCC were defined as SCC that were deeply invasive into the subcutaneous tissue 
or muscle and/or that locally recurred despite tumour-free excision margins at primary 
excision. Data about the cause of death were collected from the medical chart or the 
electronic system of the hospital.  
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Statistical methods and analyses 
In this cohort study, OTR who were included with painful skin lesions were compared with 
OTR with painless lesions and OTR with diagnoses of SCC/KA were compared with those 
with other histological diagnoses in relation to the endpoints of subsequent skin cancer, 
metastasis and/or death. 
The p-values for categorical data were calculated by Pearson’s 2-sided Chi-Square 
test and for continuous data by analyses of variance (ANOVA). Survival probabilities were 
estimated by the Kaplan-Meier method. The crude curves were used to depict survival in the 
different subgroups. We used Cox proportional hazard models to estimate hazard ratios 
(HRs) and 95% confidence intervals (CI) associated with mortality for painful compared to 
painless skin lesions and SCC/KA compared to other skin lesions. The primary outcome 
measurements were subsequent SCC/KA, BCC, metastasis and death. The starting date was 
the date of the first biopsy after the initiation of the original SCOPE-ITSCC PAIN study, and 
the end date was the end of the follow-up or the date of death of the patient. The HRs were 
adjusted for age, sex, time since transplant (i.e. time between transplant and the date of the 
first biopsy after the initiation of the original SCOPE-ITSCC PAIN study), number of SCC 
before the start of the study and, in the case of painful skin lesions, the HR was additionally 
adjusted for a histological diagnosis of SCC/KA, because these factors are potentially 
confounding factors for the associations tested. The proportional hazard assumption was 
tested by introducing an interaction term consisting of time and the group variable (i.e. SCC 
and/or KA vs. no SCC and/or KA) into the model. The hazard was supposed to be 
proportional if the interaction term was non-significant (p > 0.05). In all analyses the hazard 
was proportional. 
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SCC and KA are often considered to be part of the same skin malignancy spectrum 
and are frequently treated similarly. Therefore, the histological diagnoses were grouped into 
invasive cutaneous SCC and/or KA and all other histological diagnoses. In sensitivity 
analyses SCC were also analysed without KA, but this did not lead to significantly different 
outcomes. 
 When analysing the association between painful lesions and overall mortality risk we 
followed two strategies: firstly, we only considered the first 410 biopsies taken during the 
original study without taking any further biopsies into consideration; secondly, we considered 
all 812 skin biopsies that were taken during the original study and we counted the number of 
painful lesions per patient. 
When analysing the association between SCC/KA and overall mortality risk we 
considered the following categories of OTR with SCC: 1) OTR who were included in the 
original PAIN study with a biopsy of an SCC independent of their past medical history of 
SCC (Panel B in supplementary Figure 1); 2) OTR who were included in the original PAIN 
study with a biopsy of an SCC plus those OTR who had a previous medical history of SCC 
(Panel A in supplementary Figure 1); and 3) OTR who were included in the original PAIN 
study with a biopsy of an SCC plus those OTR who had a previous medical history of SCC 
plus those who developed an SCC during the follow-up period (Panel C in supplementary 
Figure 1), 
For all analyses, we used the software package IBM SPSS Statistics, release 23.0 
(2015; Armonk, NY). 
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Results  
The original SCOPE-ITSCC PAIN study included 122 OTR who presented with 
SCC/keratoacanthoma (KA) and 288 OTR who presented with other skin lesions at the time 
of inclusion (Table 1 and supplementary Figure 1). Of the 122 OTR with SCC/KA at 
inclusion, 88 (72.1%) already had between 1 and 100 (mean 12, median 5) SCC in their 
medical history and of the 288 OTR who presented with other skin lesions at the time of 
inclusion, 91 (31.6%) already had between 1 and 65 (mean 9, median 4) SCC in their medical 
history (Table 1 and supplementary Figure 1). 
All 410 OTR were included in the current cohort study. From 3 patients the data regarding 
SCC/KA during the follow-up were not complete and from an additional 4 patients we could 
not determine whether they were still alive or had died. 
Table 1 also shows the patient characteristics stratified by the presence of SCC/KA at 
inclusion in the SCOPE-ITSCC PAIN study. A total of 91 (74.6%) of the 122 patients with 
an SCC/KA at inclusion in the SCOPE-ITSCC PAIN study subsequently developed 1 to 125 
SCC/KA (mean 9, median 5). Altogether 73 (80.2%) of the additional 91 patients with a 
medical history of SCC before inclusion subsequently developed 1 to 64 SCC/KA (mean 7, 
median 3), and 50 (24.9%) of the 201 patients without any SCC/KA developed their first 
SCC/KA during the follow-up period (range 1 to 12, mean 3, median 2 SCC/KA) (Table 1 
and supplementary Figure 1). 
Figure 1 demonstrates the development of subsequent skin cancers following an 
earlier skin cancer. The presence of SCC/KA was predictive for the development of a 
subsequent SCC/KA (Figure 1, panel A) and BCC predicted the development of a subsequent 
BCC (Figure 1, panel B). On the other hand, the presence of a BCC did not predict a new or 
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subsequent SCC/KA (Figure 1, panel C) and SCC/KA did not predict a subsequent BCC 
(Figure 1, panel D). 
Painful skin lesions predicted an increased mortality risk (Figure 2, panel A). Since 
pain predicts SCC/KA we expected that painful SCC/KA would lead to the highest death 
rate, but this was not the case since pain alone, SCC/KA alone and painful SCC/KA all led to 
the same increased mortality rate compared to lesions without pain and non- SCC/KA lesions 
(Figure 2, panel B). An OTR with a painful lesion had double the risk of overall mortality 
when the first biopsy per patient was analysed without taking the other biopsies into account 
(Table 2a). The majority of these painful lesions consisted of SCC, Bowen’s disease and 
actinic keratoses as depicted in the legend of Table 2a. After adjustment for age, sex, 
SCC/KA as the histological diagnosis, number of SCC before inclusion in the study, and 
number of years after the transplantation there was still a 60% increased overall mortality risk 
in patients with a painful lesion (Table 2a). Taking all biopsies that were taken during the 
original study into account, we observed that the overall mortality risk increased even further 
where a patient had two or more painful lesions (Table 2b). 
When analysing the impact of the development of SCC/KA on overall mortality risk 
one can distinguish two distinct clinical questions: 1) if a patient actually presents to a clinic 
with a (first or new) SCC/KA, what is his or her prognosis regarding overall mortality risk? 
or 2) if a patient is known with an SCC/KA at present or in the past or develops an SCC/KA 
during the follow-up period what is his or her prognosis regarding overall mortality risk? The 
analyses regarding the first question are depicted in Figure 3 and Table 3a and regarding the 
second question in Table 3b. 
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A histological diagnosis of an SCC/KA, compared to a different histological 
diagnosis at the time of inclusion in the original SCOPE-ITSCC PAIN study, was associated 
with an increased overall mortality risk with a hazard ratio (adjusted for age, sex, time since 
transplant and number of SCC before the start of the study) of 1.7 (95% CI 1.0-2.8) (Figure 3 
and Table 3a). Looking at the association between SCC at any time before, at or in the 
follow-up period after the original SCOPE-ITSCC PAIN study resulted in a higher hazard 
ratio, which was after adjustment for the same factors 3.9 (95% CI: 1.6 – 9.4) (Table 3b). The 
mean number of SCC in the patients with SCC was 7.1 in the OTR who were still alive and 
7.8 in the OTR who had died (P = 0.717).  
Among the 260 patients who had developed 1 or more SCC/KA, there were 9 patients 
with metastasis of which 5 originated from an aggressive SCC. Three of the 9 patients with 
metastasis were still alive at the end of the study. Five patients died of metastatic cutaneous 
SCC, 1 patient died of bone marrow cancer. Among 10 patients with aggressive SCC (5 of 
them also had metastatic disease), 4 were still alive at the end of the study. One patient died 
of aggressive SCC located on the face without metastasis, 3 died of metastatic cutaneous 
SCC, 1 died of gastrointestinal malignancy and one died of pneumonia. Table 4a shows the 
various causes of death in the OTR who had painful lesions or no painful lesions and in Table 
4b the group with SCC/ KA is compared to the group with no SCC/KA with regard to causes 
of death. It is of interest that the mortality from systemic infection appeared to predominate 
in patients with SCC/KA, although, because of the small numbers statistical significance was 
not reached. Altogether 6 OTR died of SCC, in 5 cases because of metastatic SCC and once 
case due to an aggressive SCC without metastasis.  
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Discussion  
In our study, SCC/KA are frequently followed by new SCC/KA and similarly BCC increase 
the likelihood of the development of subsequent BCC. This trend has been reported in earlier 
papers, and our study further validated these findings.13;14 Flohil et al. reported that patients 
with a BCC had a 17-fold increased risk of developing a subsequent BCC compared with the 
BCC risk in the general population, and SCC patients had a 4-fold risk of developing a 
subsequent SCC compared with the general population.15 This type-specific predilection may 
be the consequence of particular genetic susceptibilities; e.g. for individuals in the BCC-only 
group, they may carry mutations of genes in the Hedgehog pathway or sporadic variants of 
Patched or other germ-line mutations.13 In addition, the pattern of previous sun exposure, i.e. 
continuous sun exposure for SCC and intermittent sun exposure for BCC may be another 
explanatory factor. 
We observed increased overall mortality in OTR with painful skin lesions which was 
independent of the histological diagnoses. There was also a positive association between the 
number of painful lesions and overall mortality. Our previous SCOPE-ITSCC PAIN study 
had excluded a significant association between perineural invasion and pain in SCC/KA and 
had not revealed a local factor for the pain recorded in skin lesions. Smith et al. have reported 
in a systematic review that chronic pain in general increased mortality,7 Feeny et al. have also 
reported pain in general as a predictor for mortality.16 However, the exact relationship is 
unclear. There is also a lack of published data on the relationship between acute pain and 
mortality. Potentially, skin lesions could be perceived as painful more often in people of 
lesser health with a lower threshold for the perception of pain. Alternatively, in persons with 
lesser health, SCC could behave more aggressively coupled with local induction of pain by as 
yet unknown mediators. Painful skin lesions, however, might be used as a clinical indicator to 
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guide clinicians about the poorer prognosis of this group of individuals who might benefit 
from additional management, further investigation or more intensive follow-up.8 
Our study shows that OTR who are under regular surveillance in centres dedicated to 
managing OTR-related skin problems have a very high burden of SCC/KA. Our study also 
supports the finding that OTR have an increased overall mortality risk if they are diagnosed 
with cutaneous SCC/KA. The most prevalent causes were internal malignancies and severe 
systemic infections. The contribution of metastatic cutaneous SCC to this increased mortality 
risk is limited, however, since only 10% of the mortality risk was attributable to metastatic 
SCC. Interestingly, part of the increased mortality risk compared to the OTR without 
SCC/KA could be attributed to severe systemic infections, which were observed more 
frequently in OTR with a history of SCC/KA. We do not have an explanation for this 
observation, but reduced immunity may possibly be a factor leading to more cutaneous SCC 
and at the same time an increased risk of severe systemic infections. 
The strengths of our study include the large number of patients from multiple centres 
in Europe and North America. This is also the first paper to describe the mortality risk 
associated with painful skin lesions or SCC/KA. Limitations of this study include selection 
bias resulting from including OTR predominantly in specialist OTR referral centres, and 
potential inaccuracies and missing information on cause of death in 25% of the study group 
as well as possible confounding factors like past sun exposure,  smoking and the presence of 
internal malignancies and/or cardiac disease before the diagnosis of cutaneous SCC. 
In conclusion, OTR have an increased overall mortality risk if they develop painful 
skin lesions independent of the histological diagnoses or are diagnosed with cutaneous 
SCC/KA. The development of a cutaneous SCC should warn the clinician that the patient 
may have an increased risk of internal malignancies and/or serious infections with death as a 
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possible end result. Our study highlights the need for close and long-term follow-up of OTR 
who present with SCC or painful skin lesions in view of the higher overall mortality risk 
observed in these patients.  
 
Legend to the figures 
Figure 1. The presence of squamous cell carcinoma or keratoacanthoma at enrolment predicts 
a subsequent squamous cell carcinoma or keratoacanthoma (Panel A); the presence of basal 
cell carcinoma at enrolment predicts a subsequent basal cell carcinoma (Panel B); the 
presence of basal cell carcinoma at enrolment does not predict a subsequent squamous cell 
carcinoma or keratoacanthoma (Panel C) and the presence of squamous cell carcinoma or 
keratoacanthoma at enrolment does not predict a subsequent basal cell carcinoma (Panel D). 
 
Figure 2. Decreased survival after painful skin lesions compared to painless lesions (Panel A) 
and after the occurrence of squamous cell carcinoma or keratoacanthoma and/or painful skin 
lesions (Panel B). 
 
Figure 3: A biopsy of squamous cell carcinoma or keratoacanthoma at the start of the study 
compared to a biopsy of another type of skin lesion (no SCC/KA) predicts an increased risk 
of death. 
 
Supplementary Figure 1: Schematic representation of the original SCOPE-ITSCC PAIN 
study (Panel B), history of SCC before the SCOPE-ITSCC PAIN study (Panel A) and new or 
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subsequent SCC/KA during the cohort study (Panel C). During the follow-up study 50 
SCC/KA developed in the 197 patients who had never had SCC before; 73 SCC/KA 
developed in the 91 patients who had SCC before the PAIN study, but not when a biopsy was 
taken for the original PAIN study; 21 SCC/KA developed in the 34 patients who did not have 
a history of SCC prior to the original PAIN study but presented with an SCC/KA at the start 
of the original PAIN study and 70 SCC/KA developed in the 88 patients who had a history of 
SCC before and a new SCC/KA during the PAIN study (left side of Panel C).  
The numbers indicate the number of patients in the different categories. SCC: squamous cell 
carcinoma; KA: keratoacanthoma. 
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Table 1 Characteristics of the OTR at time of inclusion in the study and during 
the follow-up. 
 
  
 
 
All patients 
 
OTR with other 
skin lesions at start 
of study* 
OTR with 
diagnoses of 
SCC/KA at start 
of study 
 
Number of OTR: (N) 
 
 
410 
 
288 
 
122 
Sex: (N (%)) 
 Women 
 Men 
 
 
125 (30.5) 
285 (69.5) 
 
89 (30.9) 
199 (69.1) 
 
36 (29.5) 
86 (70.5) 
P = 0.779 
Age at start of study (years; N (%)) 
 Younger than 50 
 50 – 59 
 60 – 69 
 70 and older 
 (Missing values) 
 
 
82 (20.1) 
99 (24.3) 
159 (39.0) 
68 (16.6) 
(2) 
 
65 (22.6) 
67 (23.3) 
109 (38.1) 
46 (16.0) 
(1) 
 
17 (14.0) 
32 (26.4) 
50 (41.3) 
22 (18.3) 
(1) 
P = 0.267 
Age at start of study (years) 
 (mean, SD) 
 
 
59.3 (11.7) 
 
58.6 (12.3) 
 
61.0 (9.8) 
P = 0.054 
Age at first transplantation (yrs.) 
 (mean, SD) 
 
 
44.3 (14.7) 
 
45.9 (14.5) 
 
40.6 (14.6) 
P = 0.001 
Years since first transplantation 
 (mean, SD) 
 
 
14.9 (10.0) 
 
12.6 (9.0) 
 
20.5 (9.9) 
P < 0.001 
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Painful lesions at start of study 
 Painless 
 Painful 
 
282 (68.8) 
128 (31.2) 
 
 
233 (80.9) 
55 (19.1) 
 
49 (40.2) 
73 (59.8) 
P < 0.001 
SCC before the start of the study 
 No SCC 
 SCC 
 
 
231 (56.3) 
179 (43.7) 
 
 
197 (68.4) 
91 (31.6) 
 
34 (27.9) 
88 (72.1) 
P < 0.001 
SCC/KA after the start of the study 
 No SCC/KA 
 SCC/KA 
 (Missing values) 
 
 
193 (47.4) 
214 (52.6) 
(3) 
 
162 (56.8) 
123 (43.2) 
(3) 
 
31 (25.4) 
91 (74.6) 
(0) 
P < 0.001 
Death 
 No 
 Yes 
 (Missing values) 
 
 
324 (80.4) 
79 (19.6) 
(7) 
 
238 (84.1) 
45 (15.9) 
(5) 
 
86 (71.7) 
34 (28.3) 
(2) 
P = 0.004 
OTR: Organ transplant recipients; SCC: squamous cell carcinoma; KA: keratoacanthoma. 
*Other skin lesions consisted of 76 (26.4%) basal cell carcinoma; 37 (12.8%) Bowen’s disease; 34 
(11.8%) actinic keratoses; 19 (6.6%) seborrheic keratoses; 14 (4.9%) common warts; 9 (3.1%) 
hyperkeratotic papillomas; 7 (2.4%) other skin malignancies; 1 (0.3%) infection and 91 (31.6%) 
miscellaneous diagnoses (mainly all kind of nevi, dermatofibroma and epidermoid cysts). 
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Table 2a Increased mortality risk in OTR with painful compared to painless 
lesions at the start of the study. 
 
 
Patients (Missing values) 
Patients still alive 
N (%) 
Patients died 
N (%) 
 
Hazard ratios 
 
Patients with painless lesions (6) 
Patients with painful lesions (1)* 
 
 
234 (84.8) 
90 (70.9) 
 
 
42 (15.2) 
37 (29.1) 
 
 
1 
2.0 (1.3;3.1) 
Adjusted for age at start of study and sex 
 
2.1 (1.4;3.3) 
Adjusted for age, sex, SCC/KA as the histological diagnosis, number of SCC 
before inclusion in the study, and number of years after the transplantation 
until inclusion in the study 
 
 
 
1.6 (0.97;2.7) 
*Painful lesions consisted of 73/122 (59.8%) SCC; 8/76 (10.5%) basal cell carcinoma; 12/37 
(32.4%) Bowen’s disease; 15/34 (44.1%) actinic keratoses; 2/19 (10.5%) seborrheic keratoses; 
1/14 (7.1%) common warts; 2/9 (22.2%) hyperkeratotic papillomas; 0/7 (0%) other skin 
malignancies; 0/1 (0%) infection and 15/91 (16.5%) miscellaneous diagnoses. 
OTR: Organ transplant recipients; SCC: squamous cell carcinoma; KA: keratoacanthoma. 
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Table 2b Increased mortality risk in OTR with painful compared to painless 
lesions at any time during the study. 
 
 
Patients 
Patients still alive 
N (%) 
Patients died 
N (%) 
 
Hazard ratios 
 
Patients with only painless lesions 
Patients with 1 painful lesion 
Pts. with 2 and more painful lesions 
 
 
210 (86.4) 
79 (73.8) 
35 (66.0) 
 
33 (13.6) 
28 (26.2) 
18 (34.0) 
 
1 
1.9 (1.2;3.2) 
2.6 (1.4;4.6) 
Adjusted for age at start of study and sex 
 
1.9 (1.2;3.2) 
3.1 (1.7;5.5) 
 
Adjusted for age, sex, SCC/KA as the histological diagnosis, number of SCC 
before inclusion in the study, and number of years after the transplantation 
until inclusion in the study 
 
 
1.6 (0.90;2.8) 
2.5 (1.3;5.0) 
 
OTR: Organ transplant recipients; SCC: squamous cell carcinoma; KA: keratoacanthoma. 
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Table 3a Increased mortality risk in OTR with cutaneous squamous cell 
carcinoma and/or keratoacanthoma compared with other skin lesions 
at inclusion in the SCOPE-ITSCC PAIN study. 
 
 
Patients (Missing values) 
Patients still alive 
N (%) 
Patients died 
N (%) 
 
Hazard ratios 
 
Patients with other skin lesions (5) 
Patients with SCC/KA (2) 
 
 
238 (84.1) 
86 (71.7) 
 
 
45 (15.9) 
34 (28.3) 
 
 
1 
1.8 (1.1;2.8) 
 
Adjusted for age at start of study and sex 1.7 (1.1;2.7) 
 
Adjusted for age, sex, number of SCC before inclusion in the study, and 
number of years after the transplantation until inclusion in the study 
 
 
1.7 (1.0;2.8) 
OTR: Organ transplant recipients; SCC: squamous cell carcinoma; KA: keratoacanthoma. 
 
 
Table 3b Increased mortality risk in OTR with cutaneous squamous cell 
carcinoma and/or keratoacanthoma when considering all SCC/KA 
developing at any time before, at the start or during the follow-up 
period of the cohort study. 
 
 
Patients (Missing values) 
Patients still alive 
N (%) 
Patients died 
N (%) 
 
Hazard ratios* 
 
Patients with other skin lesions (4) 
Patients with SCC/KA (3) 
 
 
131 (91.6) 
193 (74.2) 
 
 
12 (8.4) 
67 (25.8) 
 
 
1 
3.2 (1.7;5.9) 
Adjusted for age at start of study and sex 
 
2.7 (1.5;5.1) 
Adjustedfor age, sex, number of SCC before inclusion in the study, and 
number of years after the transplantation until inclusion in the study 
 
3.9 (1.6;9.4) 
*The occurrence of SCC/KA during the cohort study was analysed as time-dependent variable. 
OTR: Organ transplant recipients; SCC: squamous cell carcinoma; KA: keratoacanthoma. 
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Table 4a. Causes of death stratified according to painful skin lesions during 
the original SCOPE-ITSCC PAIN study. 
 
 OTR with painless lesions 
(N = 282) 
N (%) 
OTR with painful lesions 
(N = 128) 
N (%) 
No death by end of study 234 (84.8) 90 (70.9) 
Total death 42 (15.2) 37 (29.1) 
 Cardiovascular 6 (14.3) 9 (24.4) 
 Cutaneous SCC 5 (11.9) 1 (2.7) 
 Other malignancy 14 (33.3) 12 (32.4) 
 Systemic infections 5 (11.9) 5 (13.5) 
 Other reasons of death* 5 (11.9) 2 (5.4) 
 Unknown reason 7 (16.7) 8 (21.6) 
(Missing values) (6) (1) 
P = 0.015 
*Renal failure, liver failure. 
OTR: organ transplant recipients; SCC: squamous cell carcinoma. 
 
 
Table 4b. Causes of death stratified according to cutaneous squamous cell 
carcinoma and/or keratoacanthoma at any time during the study. 
 
 OTR with no SCC/KA at 
any time in the study 
(N = 147) 
N (%) 
OTR with SCC/KA at any 
time in the study 
(N = 263) 
N (%) 
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No death by end of study 131 (91.6) 193 (74.2) 
Total death 12 (8.4) 67 (25.8) 
 Cardiovascular 4 (33.4) 11 (16.3) 
 Cutaneous SCC 0 6 (9.0) 
 Other malignancy 6 (50.0) 20 (29.9) 
 Systemic infections 0 10 (14.9) 
 Other reasons of death* 1 (8.3) 6 (9.0) 
 Unknown reason 1 (8.3) 14 (20.9) 
(Missing values) (4) (3) 
P = 0.002 
*Renal failure, liver failure. 
OTR: organ transplant recipients; SCC: squamous cell carcinoma; KA: keratoacanthoma. 
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Figures 
 
 
 
 
 
 
 
Figure 1. The presence of squamous cell carcinoma or keratoacanthoma at enrolment predicts 
a subsequent squamous cell carcinoma or keratoacanthoma (Panel A); the presence of basal 
cell carcinoma at enrolment predicts a subsequent basal cell carcinoma (Panel B); the 
presence of basal cell carcinoma at enrolment does not predict a subsequent squamous cell 
carcinoma or keratoacanthoma (Panel C) and the presence of squamous cell carcinoma or 
keratoacanthoma at enrolment does not predict a subsequent basal cell carcinoma (Panel D).
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Figure 2. Decreased survival after painful skin lesions compared to painless lesions (Panel A) 
and after the occurrence of squamous cell carcinoma or keratoacanthoma and/or painful skin 
lesions (Panel B). 
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Figure 3: A biopsy of squamous cell carcinoma or keratoacanthoma at the start of the study 
compared to a biopsy of another type of skin lesion (no SCC/KA) predicts an increased risk 
of death. 
 
